CTLA4 and renal cell carcinoma: Contrastingly, among RCC patients treated with combination therapy of anti PD-1 antibody and anti CTLA-4 antibody, the prognosis of the patients with high PD-L1 expression was better than that in the patients with low PD-L1 expression2.